Is PT-141 (Bremelanotide) Legal in New York?

What Exactly Is PT-141 (Bremelanotide)?

Bremelanotide is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, primarily MC3R and MC4R in the central nervous system. Unlike sildenafil or tadalafil, it does not act on the vascular system directly. It works through neural pathways that modulate sexual desire and arousal.

The FDA approved the branded form, Vyleesi (bremelanotide 1.75 mg/0.3 mL subcutaneous injection, AMAG Pharmaceuticals), on June 21, 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi's full prescribing information is available on the FDA label database.

Mechanism of Action

Bremelanotide binds MC3R and MC4R receptors in the hypothalamus and limbic system. Activation of these receptors produces a centrally mediated increase in sexual motivation. The key Phase 3 trials, RECONNECT Study 1 and Study 2 (combined N=1,267 premenopausal women), demonstrated statistically significant improvements in satisfying sexual events and desire scores compared to placebo at 24 weeks. Published results are indexed on PubMed.

How It Differs from Other Sexual Dysfunction Treatments

PDE5 inhibitors like sildenafil work peripherally by relaxing vascular smooth muscle. Bremelanotide acts centrally, making it the only FDA-approved treatment targeting the neurological component of desire rather than physical arousal mechanics. Flibanserin (Addyi), also approved for HSDD, is a daily oral serotonin modulator with a different receptor profile and a REMS program requiring certification. The FDA's REMS database covers both agents.

Federal Legal Framework: Why It Matters for New York Residents

FDA Approval Creates the Legal Foundation

Federal law governs drug approval in the United States. Under the Federal Food, Drug, and Cosmetic Act (FDCA), a substance must be either FDA-approved or legally compounded to be dispensed to a patient. Bremelanotide clears that bar because Vyleesi holds an approved New Drug Application (NDA 210557). The FDA's drug database entry for NDA 210557 is publicly accessible.

That approval means New York prescribers are not operating in a gray area. They are prescribing a fully approved drug, subject to ordinary prescription requirements.

DEA Scheduling Status

Bremelanotide is not listed under any DEA schedule. It is not a controlled substance under the Controlled Substances Act. The DEA's list of controlled substances is maintained at the DEA Diversion Control Division. Because it carries no schedule, prescribers do not need a separate DEA-authorized controlled substance prescription form. A standard prescription pad or electronic prescription order is sufficient.

The FDA Bulks List and Compounding Status

Section 503A of the FDCA permits licensed pharmacies to compound drugs for individual patients when a valid prescription exists and the compound is not essentially a copy of a commercially available product. Section 503B permits FDA-registered outsourcing facilities to compound larger batches without patient-specific prescriptions, primarily for office stock.

The FDA maintains a Bulks List of substances that may be used in compounding. Bremelanotide is not currently on the list of bulk substances that are prohibited for 503A compounding, which means 503A pharmacies may prepare it. The FDA's current 503A bulks list is published on FDA.gov.

503B outsourcing facilities operate under stricter cGMP standards. The FDA's 503B outsourcing facility list is publicly available. For bremelanotide, a 503B facility may prepare it as office stock, but may not market it as a commercial alternative to Vyleesi.

New York State-Specific Legal Framework

New York State Department of Health and Pharmacy Licensing

New York's pharmacy licensing is governed by the New York State Education Department, Office of the Professions, and the New York State Board of Pharmacy. Compounding pharmacies operating within New York must hold a valid state pharmacy license, comply with USP <795> and USP <797> standards for non-sterile and sterile compounding, and operate within the 503A patient-specific model if they are not registered as 503B facilities. The New York State Board of Pharmacy licensing requirements are outlined at the NYS Education Department.

Out-of-state compounding pharmacies shipping into New York must hold a New York non-resident pharmacy license. New York's non-resident pharmacy registration requirements are maintained by the NYS Education Department.

Medical Practice Act and Prescribing Authority

New York Education Law Article 131 governs medical practice. Under that statute, any licensed MD or DO may prescribe bremelanotide for any indication, whether FDA-approved or off-label, provided there is a legitimate clinical basis and the prescriber documents informed consent for off-label use. New York's medical practice statutes are accessible through the NYS Legislature.

Nurse practitioners and physician assistants with prescribing privileges may also prescribe bremelanotide under their respective collaborative practice agreements. The New York State Board for Nursing publishes NP scope-of-practice guidance. NP prescribing authority in New York is described in Article 139 of the NYS Education Law.

Telehealth Prescribing in New York

New York's telehealth statute, Public Health Law Section 2999-cc, permits prescribing via synchronous audio-video telehealth after the establishment of a valid patient-provider relationship. The New York State Department of Health telehealth policy is published at health.ny.gov.

A prescriber using telehealth must conduct a thorough history and review of systems, assess contraindications (notably transient blood pressure elevation that bremelanotide produces in some patients), and document the encounter in a compliant electronic health record. The FDA label notes that bremelanotide transiently increases systolic blood pressure by approximately 6 mmHg and diastolic blood pressure by approximately 3 mmHg after each dose, effects that typically resolve within 12 hours. The full Vyleesi label with pharmacodynamic data is on the FDA database.

Clinical Evidence Supporting Prescribing Decisions

The RECONNECT Trials

The two key Phase 3 RECONNECT trials enrolled 1,267 premenopausal women with HSDD. Participants who received bremelanotide showed a statistically significant increase in satisfying sexual events compared to placebo (P<0.001) and a significant decrease on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. These outcomes are detailed in the primary NEJM publication.

At 24 weeks, 25% of bremelanotide-treated women reported a clinically meaningful improvement in desire scores versus 17% of placebo-treated women, a modest but statistically significant difference in this difficult-to-treat condition. The number needed to treat (NNT) for one additional responder was approximately 12, which prescribers should communicate during shared decision-making.

Cardiovascular Considerations

Bremelanotide is contraindicated in patients with known cardiovascular disease due to its blood pressure effects. The prescribing information carries a specific warning. The FDA MedWatch safety database contains post-market reports relevant to cardiovascular monitoring. Providers in New York telehealth settings should obtain baseline blood pressure prior to prescribing and advise patients not to use it within 12 hours of medications that also raise blood pressure.

Nausea as the Primary Adverse Effect

In the RECONNECT trials, nausea occurred in 40% of bremelanotide-treated patients versus 1% of placebo patients. Flushing occurred in 20%. Most events were transient and dose-related. The FDA adverse event summary for NDA 210557 is available through the FDA drug database. A pre-dose antiemetic such as ondansetron 4 mg is sometimes recommended, though that is itself an off-label use of the antiemetic.

Off-Label Use in Men

The FDA approved bremelanotide only for premenopausal women with HSDD. Some prescribers use it off-label for men with psychogenic erectile dysfunction or low sexual desire. Published data on this population are limited. One open-label Phase 2 trial (N=20) reported improvements in erectile function scores with intranasal bremelanotide. That earlier formulation study is indexed on PubMed. The subcutaneous formulation approved in 2019 has not been evaluated in large male trials. Prescribers undertaking off-label use in men must document clinical rationale and informed consent.

How to Get PT-141 (Bremelanotide) Legally in New York

Step 1: Establish Care with a Licensed New York Provider

The first step is a clinical encounter with a New York-licensed prescriber, either in-person or via telehealth. The provider should obtain a complete sexual health history, screen for cardiovascular risk factors, review current medications for interactions, and confirm the patient meets the diagnostic criteria for HSDD or another appropriate indication. The International Society for the Study of Women's Sexual Health (ISSWSH) publishes clinical practice guidelines for HSDD evaluation. The ISSWSH process-of-care guidelines are available through academic.oup.com.

Step 2: Receive a Lawful Prescription

After the clinical encounter, the prescriber issues a written or electronic prescription for Vyleesi (bremelanotide 1.75 mg/0.3 mL subcutaneous injection). If the provider believes a compounded formulation is clinically appropriate (for example, a different concentration or delivery method), they write a compounding prescription directed to a licensed 503A pharmacy with which the patient has a relationship.

Step 3: Fill the Prescription Through a Licensed Pharmacy

Patients may fill Vyleesi at any licensed retail pharmacy in New York. Major chains stock it or can order it. For compounded bremelanotide, the pharmacy must hold a current New York pharmacy license or a valid non-resident pharmacy license. Patients should verify pharmacy credentials through the NYS Education Department pharmacy license lookup tool before placing an order. The NYS pharmacy license verification portal is at the NYS Education Department.

Step 4: Avoid Unregulated Online Sources

Research-grade or "not for human use" bremelanotide sold on peptide vendor websites is not legal for personal injection. Those products carry no FDA-mandated quality controls, no verified sterility testing, and no pharmaceutical-grade purity assurance. Purchasing such products and self-administering them violates the FDCA's prohibition on the distribution of unapproved new drugs. The FDA's guidance on unapproved drugs is published at FDA.gov. The FDA has issued warning letters to multiple peptide vendors. The FDA warning letter database documents specific enforcement actions.

Insurance Coverage and Cost in New York

Vyleesi is not covered by most commercial insurance plans in New York, and it is not covered by Medicaid. The average wholesale price per auto-injector is approximately $1,000 to $1,200. AMAG Pharmaceuticals offers a savings card program for eligible commercially insured patients that may reduce out-of-pocket cost significantly. Drug pricing data is tracked by the FDA through the National Drug Code directory.

Compounded bremelanotide from a 503A pharmacy typically costs $150 to $400 per vial depending on concentration and quantity, though prices vary by pharmacy. Patients should request a Certificate of Analysis confirming purity and sterility testing before accepting any compounded product.

Red Flags: What Distinguishes a Legal Source from an Illegal One

A prescription from a provider who never conducts a clinical evaluation is not a lawful prescription under New York law. A pharmacy operating without a New York license or a valid non-resident pharmacy license cannot legally ship bremelanotide into New York. A vendor labeling bremelanotide as "research chemical" or "not for human use" is not operating within the pharmaceutical supply chain.

The New York State Office of Professional Medical Conduct (OPMC) investigates prescribers who issue prescriptions without a valid clinical basis. The OPMC complaint and investigation process is described at the NYSDOH website. Patients who receive prescriptions from such sources bear no criminal liability under the FDCA for simple possession, but they carry full clinical risk from an unverified product.

Monitoring After Starting Bremelanotide

Prescribers should schedule a follow-up visit at 8 to 12 weeks to assess efficacy and tolerability. Blood pressure should be rechecked, particularly in patients who reported any cardiovascular symptoms after the first dose. The Endocrine Society's clinical practice guidelines on female sexual dysfunction recommend systematic outcome measurement using validated tools such as the FSFI (Female Sexual Function Index) at follow-up. The Endocrine Society's clinical guidelines are indexed at endocrine.org.

If a patient has not had at least one satisfying sexual event improvement by week 8 and does not note any subjective improvement in desire, the prescribing guidelines suggest reassessing the diagnosis and considering discontinuation. Long-term safety data beyond 52 weeks of use have not been established in clinical trials. The FDA's post-market safety surveillance program for Vyleesi is active through MedWatch.